A detailed history of Ronald Blue Trust, Inc. transactions in Arvinas, Inc. stock. As of the latest transaction made, Ronald Blue Trust, Inc. holds 353 shares of ARVN stock, worth $6,403. This represents 0.0% of its overall portfolio holdings.

Number of Shares
353
Previous 339 4.13%
Holding current value
$6,403
Previous $8,000 25.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 22, 2025

BUY
$17.83 - $28.04 $249 - $392
14 Added 4.13%
353 $6,000
Q3 2024

Oct 17, 2024

BUY
$23.66 - $32.73 $6,790 - $9,393
287 Added 551.92%
339 $8,000
Q2 2024

Jul 18, 2024

BUY
$24.46 - $40.4 $1,271 - $2,100
52 New
52 $1,000
Q2 2023

Jul 14, 2023

BUY
$21.73 - $31.43 $86 - $125
4 New
4 $0
Q4 2022

Jan 17, 2023

BUY
$32.47 - $57.24 $162 - $286
5 Added 125.0%
9 $0
Q3 2022

Oct 21, 2022

BUY
$41.87 - $57.99 $167 - $231
4 New
4 $0

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $965M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Ronald Blue Trust, Inc. Portfolio

Follow Ronald Blue Trust, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ronald Blue Trust, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ronald Blue Trust, Inc. with notifications on news.